What is the share price of Anlon Healthcare Ltd (AHCL) today?
The share price of AHCL as on 31st July 2026 is ₹14.61. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Anlon Healthcare Ltd (AHCL) share?
The past returns of Anlon Healthcare Ltd (AHCL) share are- Past 1 week: -2.66%
- Past 1 month: -9.14%
- Past 3 months: 9.85%
- Past 6 months: 20.62%
- Past 1 year: 59.27%
- Past 3 years: N/A%
- Past 5 years: 59.27%
What are the peers or stocks similar to Anlon Healthcare Ltd (AHCL)?
The peers or stocks similar to Anlon Healthcare Ltd (AHCL) include:What is the market cap of Anlon Healthcare Ltd (AHCL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Anlon Healthcare Ltd (AHCL) is ₹776.54 Cr as of 31st July 2026.What is the 52 week high and low of Anlon Healthcare Ltd (AHCL) share?
The 52-week high of Anlon Healthcare Ltd (AHCL) is ₹17.28 and the 52-week low is ₹9.08.What is the PE and PB ratio of Anlon Healthcare Ltd (AHCL) stock?
The P/E (price-to-earnings) ratio of Anlon Healthcare Ltd (AHCL) is 27.23. The P/B (price-to-book) ratio is 9.66.Which sector does Anlon Healthcare Ltd (AHCL) belong to?
Anlon Healthcare Ltd (AHCL) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Anlon Healthcare Ltd (AHCL) shares?
You can directly buy Anlon Healthcare Ltd (AHCL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Anlon Healthcare Ltd
AHCL Share Price
NSE₹14.610.62% (+0.09)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
AHCL Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
AHCL Performance & Key Metrics
AHCL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 24.54 | 9.66 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.85 | 6.02 | 0.50% |
AHCL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
AHCL Company Profile
Anlon Healthcare Ltd manufactures high purity advanced pharmaceutical intermediates and active pharmaceutical ingredients used in pharmaceutical formulations, nutraceuticals, personal care, and animal health products.
SUNPHARMA
PE Ratio
41.60
41.60
1Y Return
16.63%
16.63%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
90.07
90.07
1Y Return
36.90%
36.90%
Buy Reco %
82.14
82.14
CIPLA
PE Ratio
30.68
30.68
1Y Return
5.24%
5.24%
Buy Reco %
63.89
63.89
ZYDUSLIFE
PE Ratio
22.30
22.30
1Y Return
16.19%
16.19%
Buy Reco %
55.17
55.17
LUPIN
PE Ratio
20.71
20.71
1Y Return
25.19%
25.19%
Buy Reco %
55.56
55.56
AHCL Sentiment Analysis
AHCL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
AHCL Stock Summary · June 2026
Management characterized the quarter as strong full‑year growth offset by near‑term margin pressure as the business scales. FY26 total income rose 42.98% to INR 172.22 crore and EBITDA increased 47.55% to INR 47.77 crore, though Q4 reported PAT declined to INR 11.07 crore amid higher operating and development spend tied to scaling and two recent facility integrations. Management emphasized disciplined pricing, capacity monetization and regulatory commercialization—including plans to commercialize 5–7 DMF‑linked products in FY27, file three to five DMFs and expand capacity after recent acquisitions—to drive a targeted ~30% revenue CAGR and mid‑20s consolidated EBITDA margins (cited ranges around 24–30%). They acknowledged acute margin volatility from raw‑material inflation, locked purchase orders and integration costs, noting force majeure actions and gradual customer acceptance of higher prices as partial mitigation. Near term they reiterated FY27 revenue visibility of INR 380–400 crore based on a consolidated order book and conversion assumptions, expect consolidated utilization to move from ~62–65% toward planning assumptions near 80%, and aim for operating cash flow to turn positive on an annual basis by end‑FY27 while funding Rajkot capex largely with bank debt and internal accruals.
AHCL Stock Growth Drivers
AHCL Stock Growth Drivers
8Strong FY26 financial performance and clear near‑term revenue momentum
The company delivered robust FY26 results with total income up 42.98% year‑on‑year to INR 172.22
Expanded and strengthened manufacturing, R&D and regulatory platform
The company has materially bolstered its execution platform through capacity expansion, R&D investment and regulatory
AHCL Stock Challenges
AHCL Stock Challenges
5Acute input‑cost volatility and margin compression
The company is facing pronounced margin pressure driven by sharp raw‑material, solvent and catalyst inflation
Severe working‑capital and liquidity strain from elevated receivables and inventories
The balance sheet and cash flow profile show material stress from extended collections and higher
AHCL Forecast
AHCL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
AHCL
AHCL
Income
Balance Sheet
Cash Flow
Quarterly Normal View
AHCL Income Statement
AHCL Income Statement
Quarterly Normal View
| Quarter | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 48.97 | 33.31 | 52.23 | 35.78 | 50.90 | 87.62 | ||||||
Operating & Other expenses | 31.74 | 27.06 | 38.49 | 23.30 | 35.60 | 71.97 | ||||||
EBITDA | 17.23 | 6.25 | 13.74 | 12.48 | 15.30 | 15.65 | ||||||
| Depreciation/Amortization | 0.83 | 0.43 | 0.45 | 0.35 | 0.29 | 1.07 | ||||||
| PBIT | 16.40 | 5.82 | 13.29 | 12.13 | 15.01 | 14.58 | ||||||
| Interest & Other Items | 0.91 | 0.82 | 0.84 | 1.51 | 0.57 | 0.92 | ||||||
| PBT | 15.49 | 5.00 | 12.45 | 10.62 | 14.44 | 13.66 | ||||||
| Taxes & Other Items | -1.16 | 1.46 | 3.13 | 5.46 | 3.94 | 7.00 | ||||||
| Net Income | 16.65 | 3.54 | 9.32 | 5.16 | 10.50 | 6.66 | ||||||
| EPS | 5.15 | 0.89 | 0.17 | 0.11 | 0.23 | 0.16 |
AHCL Company Updates
FY 2026FY 2026
Investor Presentation
Jun 3PDF
Feb 19PDF
Nov 19PDF
AHCL Stock Peers
AHCL Past Performance & Peer Comparison
AHCL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Anlon Healthcare Ltd | 27.23 | 9.66 | — |
| Sun Pharmaceutical Industries Ltd | 41.60 | 5.69 | 0.80% |
| Torrent Pharmaceuticals Ltd | 90.07 | 11.08 | 0.66% |
| Cipla Ltd | 30.68 | 3.45 | 0.88% |
AHCL Stock Price Comparison
Compare AHCL with any stock or ETFCompare AHCL with any stock or ETF
AHCL
AHCL Holdings
AHCL Shareholdings
AHCL Promoter Holdings Trend
AHCL Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
AHCL Institutional Holdings Trend
AHCL Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 2.74%
Increased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has increased by 1.35%
AHCL Shareholding Pattern
AHCL Shareholding Pattern
AHCL Shareholding History
AHCL Shareholding History
Foreign Institutions
smallcases containing AHCL stock
smallcases containing AHCL stock
Looks like this stock is not in any smallcase yet.
AHCL Events
AHCL Events
AHCL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
AHCL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
AHCL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
AHCL has not given any dividends in last 5 years
AHCL Dividends
AHCL Dividends
Hmm, looks like data is unavailable here. Please come back after some timeAHCL Stock News & Opinions
AHCL Stock News & Opinions
Articles & Videos
Corporate
Corporate
Anlon Healthcare’s income rose 163% year-on-year, fueled by acquisition of Remember IndiaAnlon Healthcare Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026, reporting a total income of Rs 87.62 crore, a 163.02% year-on-year increase, with Rs 15.65 crore in EBITDA, up 150.14%, and Rs 8.28 crore in profit after tax, a 133.13% rise. The company acquired a 63.98% stake in Remember India Health Links Pvt. Ltd. for Rs 5.38 crore on May 8, 2026, expanding into the Finished Dosage Formulations (FDF) segment and gaining access to 30+ formulation dossiers, while also broadening its market presence across B2B APIs, domestic retail, and hospital markets.
1 day agoCapital Market - Live
Earnings
Earnings
Anlon Healthcare consolidated net profit rises 87.61% in the June 2026 quarterNet profit of Anlon Healthcare rose 87.61% to Rs 6.66 crore in the quarter ended June 2026 as against Rs 3.55 crore during the previous quarter ended June 2025. Sales rose 162.94% to Rs 87.56 crore in the quarter ended June 2026 as against Rs 33.30 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales87.5633.30 163 OPM %17.8018.74 - PBDT14.735.43 171 PBT13.665.00 173 NP6.663.55 88 Powered by Capital Market - Live
2 days agoCapital Market - Live
Corporate
Corporate
Anlon Healthcare schedules board meetingAnlon Healthcare will hold a meeting of the Board of Directors of the Company on 30 July 2026.
4 days agoCapital Market - Live
Earnings
Earnings
Anlon Healthcare consolidated net profit declines 36.94% in the March 2026 quarterNet profit of Anlon Healthcare declined 36.94% to Rs 10.50 crore in the quarter ended March 2026 as against Rs 16.65 crore during the previous quarter ended March 2025. Sales rose 4.01% to Rs 50.89 crore in the quarter ended March 2026 as against Rs 48.93 crore during the previous quarter ended March 2025. For the full year,net profit rose 38.94% to Rs 28.51 crore in the year ended March 2026 as against Rs 20.52 crore during the previous year ended March 2025. Sales rose 42.96% to Rs 171.97 crore in the year ended March 2026 as against Rs 120.29 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales50.8948.93 4 171.97120.29 43 OPM %30.0635.13 -27.6326.78 - PBDT14.7316.32 -10 44.0328.66 54 PBT14.4415.49 -7 42.5126.89 58 NP10.5016.65 -37 28.5120.52 39 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Anlon Healthcare to table resultsAnlon Healthcare will hold a meeting of the Board of Directors of the Company on 29 May 2026.
2 months agoCapital Market - Live
Corporate
Corporate
Anlon Healthcare to convene board meetingAnlon Healthcare will hold a meeting of the Board of Directors of the Company on 6 March 2026.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Earnings
Anlon Healthcare reports standalone net profit of Rs 5.15 crore in the December 2025 quarterNet profit of Anlon Healthcare reported to Rs 5.15 crore in the quarter ended December 2025 as against net loss of Rs 2.49 crore during the previous quarter ended December 2024. Sales rose 280.13% to Rs 35.58 crore in the quarter ended December 2025 as against Rs 9.36 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales35.589.36 280 OPM %34.686.20 - PBDT10.96-0.29 LP PBT10.61-0.29 LP NP5.15-2.49 LP Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Anlon Healthcare to announce Quarterly ResultAnlon Healthcare will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Earnings
Anlon Healthcare standalone net profit rises 259.85% in the September 2025 quarterNet profit of Anlon Healthcare rose 259.85% to Rs 9.32 crore in the quarter ended September 2025 as against Rs 2.59 crore during the previous quarter ended September 2024. Sales rose 115.97% to Rs 52.20 crore in the quarter ended September 2025 as against Rs 24.17 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales52.2024.17 116 OPM %26.3231.07 - PBDT12.906.63 95 PBT12.456.16 102 NP9.322.59 260 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Anlon Healthcare to table resultsAnlon Healthcare will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 60.18%, vs industry avg of 12.48%
Over the last 5 years, market share increased from 0.01% to 0.03%